Clinical considerations in choosing an antiarrhythmic agent

D. P. Zipes

Research output: Contribution to journalArticle

Abstract

Classification and pathophysiology of arrhythmias, principles of drug selection, methods for monitoring drug efficacy, and risk of proarrhythmic events are reviewed. The need for drug therapy is influenced by the arrhythmia type. Treatment is most important for life-threatening arrhythmias; infrequently occurring, non-life-threatening arrhythmias generally do not require drug therapy. In general, drug effects are not predictable for patients with ventricular tachyarrhythmias, and drug classifications are of limited value in selecting an antiarrhythmic agent. However, many of the supraventricular tachycardias are exceptions to this rule. Because drug selection is mainly empiric, a drug's adverse-effect profile and proarrhythmic potential are important considerations. The four most commonly used methods for assessing drug efficacy are serial long-term electrocardiography, serial exercise testing, electrophysiologic-pharmacologic testing, and measurement of plasma drug concentrations. Because of the uncertain relationship between plasma drug concentration and efficacy, combined electrocardiographic and electrophysiologic-pharmacologic testing usually is preferred. Determination of the need for drug therapy, selection of the correct antiarrhythmic agent, and documentation of sustained efficacy are required for making appropriate decisions about antiarrhythmic therapy.

Original languageEnglish
Pages (from-to)1-5
Number of pages5
JournalClinical Pharmacy
Volume6
Issue number3 II
StatePublished - 1987

Fingerprint

Pharmaceutical Preparations
Cardiac Arrhythmias
Drug Therapy
Supraventricular Tachycardia
Drug Monitoring
Tachycardia
Documentation
Decision Making
Electrocardiography
Exercise
Therapeutics

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Clinical considerations in choosing an antiarrhythmic agent. / Zipes, D. P.

In: Clinical Pharmacy, Vol. 6, No. 3 II, 1987, p. 1-5.

Research output: Contribution to journalArticle

Zipes, D. P. / Clinical considerations in choosing an antiarrhythmic agent. In: Clinical Pharmacy. 1987 ; Vol. 6, No. 3 II. pp. 1-5.
@article{4ac4ab3a3c8d43fe94d3c32646ec56ac,
title = "Clinical considerations in choosing an antiarrhythmic agent",
abstract = "Classification and pathophysiology of arrhythmias, principles of drug selection, methods for monitoring drug efficacy, and risk of proarrhythmic events are reviewed. The need for drug therapy is influenced by the arrhythmia type. Treatment is most important for life-threatening arrhythmias; infrequently occurring, non-life-threatening arrhythmias generally do not require drug therapy. In general, drug effects are not predictable for patients with ventricular tachyarrhythmias, and drug classifications are of limited value in selecting an antiarrhythmic agent. However, many of the supraventricular tachycardias are exceptions to this rule. Because drug selection is mainly empiric, a drug's adverse-effect profile and proarrhythmic potential are important considerations. The four most commonly used methods for assessing drug efficacy are serial long-term electrocardiography, serial exercise testing, electrophysiologic-pharmacologic testing, and measurement of plasma drug concentrations. Because of the uncertain relationship between plasma drug concentration and efficacy, combined electrocardiographic and electrophysiologic-pharmacologic testing usually is preferred. Determination of the need for drug therapy, selection of the correct antiarrhythmic agent, and documentation of sustained efficacy are required for making appropriate decisions about antiarrhythmic therapy.",
author = "Zipes, {D. P.}",
year = "1987",
language = "English",
volume = "6",
pages = "1--5",
journal = "Clinical Pharmacy",
issn = "0278-2677",
publisher = "American Society of Hospital Pharmacists",
number = "3 II",

}

TY - JOUR

T1 - Clinical considerations in choosing an antiarrhythmic agent

AU - Zipes, D. P.

PY - 1987

Y1 - 1987

N2 - Classification and pathophysiology of arrhythmias, principles of drug selection, methods for monitoring drug efficacy, and risk of proarrhythmic events are reviewed. The need for drug therapy is influenced by the arrhythmia type. Treatment is most important for life-threatening arrhythmias; infrequently occurring, non-life-threatening arrhythmias generally do not require drug therapy. In general, drug effects are not predictable for patients with ventricular tachyarrhythmias, and drug classifications are of limited value in selecting an antiarrhythmic agent. However, many of the supraventricular tachycardias are exceptions to this rule. Because drug selection is mainly empiric, a drug's adverse-effect profile and proarrhythmic potential are important considerations. The four most commonly used methods for assessing drug efficacy are serial long-term electrocardiography, serial exercise testing, electrophysiologic-pharmacologic testing, and measurement of plasma drug concentrations. Because of the uncertain relationship between plasma drug concentration and efficacy, combined electrocardiographic and electrophysiologic-pharmacologic testing usually is preferred. Determination of the need for drug therapy, selection of the correct antiarrhythmic agent, and documentation of sustained efficacy are required for making appropriate decisions about antiarrhythmic therapy.

AB - Classification and pathophysiology of arrhythmias, principles of drug selection, methods for monitoring drug efficacy, and risk of proarrhythmic events are reviewed. The need for drug therapy is influenced by the arrhythmia type. Treatment is most important for life-threatening arrhythmias; infrequently occurring, non-life-threatening arrhythmias generally do not require drug therapy. In general, drug effects are not predictable for patients with ventricular tachyarrhythmias, and drug classifications are of limited value in selecting an antiarrhythmic agent. However, many of the supraventricular tachycardias are exceptions to this rule. Because drug selection is mainly empiric, a drug's adverse-effect profile and proarrhythmic potential are important considerations. The four most commonly used methods for assessing drug efficacy are serial long-term electrocardiography, serial exercise testing, electrophysiologic-pharmacologic testing, and measurement of plasma drug concentrations. Because of the uncertain relationship between plasma drug concentration and efficacy, combined electrocardiographic and electrophysiologic-pharmacologic testing usually is preferred. Determination of the need for drug therapy, selection of the correct antiarrhythmic agent, and documentation of sustained efficacy are required for making appropriate decisions about antiarrhythmic therapy.

UR - http://www.scopus.com/inward/record.url?scp=0023213958&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023213958&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 1

EP - 5

JO - Clinical Pharmacy

JF - Clinical Pharmacy

SN - 0278-2677

IS - 3 II

ER -